In a dramatic turn of events, Skye Bioscience, Inc. finds itself at the center of a class action lawsuit, accused of misleading investors about the potential of its lead product, nimacimab. The lawsuit, filed on behalf of shareholders, aims to recover losses incurred between November 4, 2024, and October 3, 2025, due to alleged securities fraud. Investors were reportedly led to believe that nimacimab was more effective than it actually was, with its clinical, regulatory, and commercial prospects being overstated. This has resulted in claims that the company’s public statements were materially false and misleading.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
For those who have suffered losses in Skye Bioscience stock during this period, there is an opportunity to seek recovery without any cost or obligation. Affected shareholders are encouraged to visit the provided link to learn more about their rights.
The legal proceedings are being spearheaded by Levi & Korsinsky LLP, a firm renowned for its expertise in securities litigation. With a track record of securing hundreds of millions of dollars for shareholders and a team of over 70 employees, Levi & Korsinsky has been recognized as one of the top securities litigation firms in the United States for seven consecutive years.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171